18181-93-6

Basic information

• Product Name: 2,4-Diamino-6,7-diphenyl-pteridine
• Synonyms: 2,4-Diamino-6,7-diphenyl-pteridine
• CAS NO: 18181-93-6
• Molecular Formula: C₁₈H₁₄N₆
• Molecular Weight: 314.34396
• Mol File: 18181-93-6.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 567.2°Cat760mmHg
• Flash Point: 331.5°C
• Appearance: /
• Density: 1.357g/cm³
• Vapor Pressure: 6.97E-13mmHg at 25°C
• Refractive Index: 1.747
• CAS DataBase Reference: 2,4-Diamino-6,7-diphenyl-pteridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Diamino-6,7-diphenyl-pteridine(18181-93-6)
• EPA Substance Registry System: 2,4-Diamino-6,7-diphenyl-pteridine(18181-93-6)

Safety Data

• Hazardous Substances Data: 18181-93-6(Hazardous Substances Data)

Usage

General Description

2,4-Diamino-6,7-diphenyl-pteridine is a chemical compound that belongs to the class of pteridine derivatives. It is a heterocyclic compound consisting of a pteridine core with two amino and two phenyl groups attached to it. 2,4-Diamino-6,7-diphenyl-pteridine is commonly used in the synthesis of various pharmaceuticals and dyes. It has been studied for its potential biological activities, including anti-cancer, anti-viral, and anti-inflammatory properties. Additionally, it has been explored for its potential use as a fluorescent probe in biological and chemical applications. The unique structure of 2,4-Diamino-6,7-diphenyl-pteridine makes it a versatile compound with diverse potential applications in the fields of medicine, chemistry, and biotechnology.

InChI:InChI=1/C18H14N6/c19-16-15-17(24-18(20)23-16)22-14(12-9-5-2-6-10-12)13(21-15)11-7-3-1-4-8-11/h1-10H,(H4,19,20,22,23,24)

Upstream product

• 1004-74-6 2,4,5,6-tetraaminopyrimidine 
• 134-81-6 benzil 
• 78-93-3 butanone 
• 451-40-1 phenyl benzyl ketone 
• 1006-23-1 5-nitroso-2,4,6-triaminopyrimidine 
• 14893-05-1 4-amino-6,7-diphenyl-1H-pteridine-2-thione 
• 15263-43-1 2-methylsulfanyl-6,7-diphenyl-pteridin-4-ylamine 
• 593-85-1 diguanidine carbonate 
• 34122-24-2 3-chloro-5,6-diphenyl-pyrazine-2-carbonitrile 
• 152941-76-9 4-amino-6,7-diphenyl-2-pivaloylaminopteridine 
• 5392-28-9 2,4,5,6-tetraaminopyrimidine sulfate 
• 152941-74-7 6,7-diphenyl-2-pivaloylamino-4-<1'-(1,2,4-triazolyl)>pteridine 
• 152941-73-6 6,7-diphenyl-2-pivaloylamino-4(3H)-pteridinone 
• 522614-06-8 N-(3,4-dihydro-4-oxo-6,7-diphenylpteridin-2-yl)acetamide 

Downstream Products

• 7596-72-7 N²,N⁴-bis-(2-hydroxy-ethyl)-6,7-diphenyl-pteridine-2,4-diyldiamine 
• 113455-22-4 N⁴-(2-dimethylamino-ethyl)-6,7-diphenyl-pteridine-2,4-diyldiamine 
• 5458-93-5 N²,N⁴-bis-(3-dimethylamino-propyl)-6,7-diphenyl-pteridine-2,4-diyldiamine 
• 114202-17-4 N⁴-(3-diethylamino-propyl)-6,7-diphenyl-pteridine-2,4-diyldiamine 
• 116810-24-3 N²,N⁴-bis-(3-diethylamino-propyl)-6,7-diphenyl-pteridine-2,4-diyldiamine 
• 7509-56-0 N²,N⁴-dibenzyl-6,7-diphenyl-pteridine-2,4-diyldiamine 
• 108370-22-5 2-amino-1-methyl-6,7-diphenyl-1H-pteridin-4-one-imine 
• 17376-91-9 6,7-diphenylpterin 

Relevant articles and documents

Designing Dihydrofolate Reductase Inhibitors as X-ray Radiosensitizers to Reverse Radioresistance of Cervical Cancer

X-ray radiotherapy has been widely used in the treatment of cervical cancer, a common gynecologic malignant tumor. However, the therapeutic efficacy tends to be indistinctive. One major reason for this is amplification of the dihydrofolate reductase (DHFR) gene, which causes an increase in DHFR activity and attenuation of the treatment effect. To solve this problem, we synthesized a series of DHFR inhibitors derived from methotrexate (MTX) analogues as radiotherapy sensitizers. Activity screening revealed that compound 2a exerted the best inhibitory effect toward DHFR activity. In combination with X-ray radiotherapy (4 Gy), 2a showed much more prominent antiproliferative activity on cervical cancer cells than 2a or X-rays alone and revealed higher selectivity and radiosensitization than MTX. In vitro experiments showed that 2a + X-rays significantly induced cell apoptosis, as revealed by the increase in the Sub-G1 population and activation of caspase 3, 8, and 9. The in vivo antitumor effect demonstrated that in the presence of X-rays, 2a effectively suppressed tumor growth and did not cause obvious side effects. In conclusion, as a DHFR inhibitor, 2a successfully reversed the radioresistance problem induced by radiotherapy and greatly promoted the therapeutic effect. This is a promising candidate for tumor treatment that deserves further research and development. This study clearly demonstrates that DHFR inhibitors could be developed as promising radiosensitizers in the treatment of cervical cancer and that further research to improve their activity and potential in future clinical use is deserved.

PROTECTION AND DEPROTECTION OF FUSED 2-AMINO-4(3H)PYRIMIDONES: CONVERSION OF PTERINS AND 5-DEAZAPTERINS TO 2,4-DIAMINO DERIVATIVES

5-Deazapterins and pterins are readily converted to their 4-deoxy-4-amino derivatives (a lactam-to-amidine conversion) by reaction with 4-chlorophenyl phosphorodichloridate and 1,2,4-triazole to give intermediate 4- derivatives, followed by reaction with aqueous ammonia.Some anomalous results obtained by application of the Mitsunobu reaction (normally a lactam-to-lactim ether conversion) to 5-deazapterins are detailed.